a-163

Triaziquone is an alkylating agent that can react with DNA to form intrastrand crosslinks.

A 16316-C is a water soluble basic antibiotic, it is isolated from Streptoverticillium eurocidicus.

The Anti-CEACAM7 Antibody (P3-7B) is a chimeric monoclonal antibody of the mouse IgG1, κ class, targeting CEACAM7 (human origin). Its isotype control is MouseIgG1kappa, Isotype Control.

Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. It reduces the release of cytokines IL-8 and IL-6 in SKOV3 cells and blocks tumor cell migration triggered by LPA. In Matrigel plug and CNV models, Lpathomab decreases angiogenesis. In the CCI mouse model, it inhibits brain injury. This compound can be utilized for research on brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: HumanIgG1kappa, Isotype Control.

ASP-1948 is a human monoclonal antibody targeting NRP1/VEGF165R/CD34. It is capable of reversing the inhibitory effects of regulatory T cells and can be applied in the study of solid tumors.

Sym023 is a human monoclonal antibody (mAb) that targets TIM-3/HAVCR2/CD366. It enhances immune stimulation and exhibits anti-tumor activity, making it a valuable research tool for studies on non-small cell lung cancer, solid tumors, and lymphoma.

Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. It can inhibit the binding of sCD70 to human CD27ECD-Fc. Anti-CD27 Antibody (M2191) is applicable in anti-tumor immunology research. The recommended isotype control is Human IgG1 kappa, Isotype Control.

GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. It alleviates pulmonary neutrophilia, the release of inflammatory cytokines, and signs of endothelial injury in bronchoalveolar lavage fluid and serum samples. GSK1995057 is used in research on acute lung injury and adult respiratory distress syndrome. The recommended isotype control is dAb (VHH-His).

CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. It is utilized in psoriasis research. The recommended isotype control for this compound is Human IgG1 kappa, Isotype Control.

ALD1910 is a humanized monoclonal antibody targeting PACAP38 and PACAP27. It inhibits PACAP signaling through pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a non-linear epitope within PACAP and prevents its binding to cell surfaces. It is useful for studying PACAP-mediated migraines.

ADI-65533 is a human IgG1 monoclonal antibody that targets Envelopment polyprotein, M polyprotein. It is useful for research on hantavirus infections. The recommended isotype control is Human IgG1 kappa, Isotype Control.

INCAGN1949 is a human IgG1 monoclonal antibody (mAb) that targets TNFRSF4/OX40/CD134. It selectively depletes regulatory T cells within tumors.

FAZ-053 is a human monoclonal antibody (mAb) that targets B7-H1/PD-L1/CD274. It inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. Additionally, FAZ-053 enhances the production of interleukin-2 and is applicable in research studies on advanced alveolar soft part sarcoma (ASPS), chordoma, and triple-negative breast cancer.

SKLB-163 is a small-molecule inhibitor and a RhoGDI inhibitor with oral bioactivity, cell permeability, and selectivity. This compound induces tumor cell apoptosis, inhibits proliferation and migration, and enhances radiosensitivity by downregulating RhoGDI, activating the JNK-1/caspase-3 pathway, and suppressing Akt and p44/42 MAPK phosphorylation.

EM 163 is a TIR-TIR interaction inhibitor, which is a TIR (Toll/interleukin-1 receptor) structural domain mimic of the MyD88 protein. EM 163 targets the TIR structural domain in the IL-1 receptor and blocks the interaction with MyD88. EM 163 inhibits the production of inflammatory cytokines in vivo caused by staphylococcal enterotoxin B (SEB). EM 163 protects mice from SEB shock-induced death. In rat hippocampal neurons in vitro, EM 163 blocked the activation of p38 and the inhibitory effect of IL-1β on chemically induced long-term potentiation (LTP)-triggered protein synthesis.

NRX-103095 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP and enhances the affinity of pSer33/Ser37 β-catenin for β-TrCP with an EC50 of 163 nM.

Harman hydrochloride can directly induce CYP1A1 gene expression in an AhR-dependent manner and may represent a novel mechanism by which harman promotes mutagenicity, co-mutagenicity and carcinogenicity.

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC) with IC50 values of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively.

Ens-163 phosphate is a muscarinic M1 receptor agonist. It is selective.

Pomalidomide-PEG2-Oms is a conjugate of the E3 ligase ligand and linker, serving as a component of EGFR PROTAC DDC-01-163.

DDC-01-163 is a selective PROTAC degrader targeting EGFR mutants, with an IC50 of 45 nM.

JBJ-07-149 is an inhibitor of EGFRL858R/T790M with an IC50 of 1.1 nM. It suppresses the proliferation of Ba/F3 cells with IC50 values of 4.9 μM when used alone, and 0.148 μM when combined with Cetuximab. Additionally, JBJ-07-149 can serve as a target protein ligand for synthesizing [DDC-01-163].

E3 Ligase Ligand-linker Conjugate 163 is the E3 ligase ligand (E3 Ligase Ligand 58)-linker conjugate component of AH078, a PROTAC that selectively degrades CK1δ and CK1ε. It is utilized in research related to circadian rhythm disorders.

AH078 (compound 37) is a selective PROTAC degrader targeting CK1δ and CK1ε with low selectivity for CK1α. AH078 consists of a PROTAC linker (black part) Monomethyl octanoate, a target protein ligand (red part) CK1δ/CK1ε ligand-1, and an E3 ligase ligand (blue part) E3 Ligase Ligand 58. The E3 ligase ligand combined with the linker forms the conjugate E3 Ligase Ligand-linker Conjugate 163.